Cyclophilin A and CD147 associate with progression of diabetic nephropathy

References

• Taal MW, Brenner BM. Predicting initiation and progression of chronic kidney disease: developing renal risk scores. Kidney Int. 2006;70(10):1694–1705.
   PubMed Web of Science ®Google Scholar
• Inker LA, Levey AS, Pandya K, et al. Early change in proteinuria as a surrogate endpoint for kidney disease progression: an individual patient meta-analysis. Am J Kidney Dis. 2014;64(1):74–85.
   PubMed Web of Science ®Google Scholar
• Ninomiya T, Perkovic V, de Galan BE, et al. Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. J Am Soc Nephrol. 2009;20(8):1813–1821.
   PubMed Web of Science ®Google Scholar
• Tegeder I, Schumacher A, John S, et al. Elevated serum cyclophilin levels in patients with severe sepsis. J Clin Immunol. 1997;17(5):380–386.
   PubMed Web of Science ®Google Scholar
• Yang Y, Lu N, Zhou J, et al. Cyclophilin A up-regulates MMP-9 expression and adhesion of monocytes/macrophages via CD147 signalling pathway in rheumatoid arthritis. Rheumatol Oxf Engl. 2008;47(9):1299–1310.
   PubMed Web of Science ®Google Scholar
• Yao Q, Li M, Yang H, et al. Roles of cyclophilins in cancers and other organ systems. World J Surg. 2005;29(3):276–280.
   PubMed Web of Science ®Google Scholar
• Satoh K. Cyclophilin A in cardiovascular homeostasis and diseases. Tohoku J Exp Med. 2015;235(1):1–15.
   PubMed Web of Science ®Google Scholar
• Kosugi T, Maeda K, Sato Waichi, et al. CD147 (EMMPRIN/basigin) in kidney diseases: from an inflammation and immune system viewpoint. Nephrol Dial Transplant. 2015;30(7):1097–1103.
   PubMed Web of Science ®Google Scholar
• Tsai SF, Su CW, Wu MJ, et al. Urinary cyclophilin A as a new marker for diabetic nephropathy: A cross-sectional analysis of diabetes mellitus. Medicine. 2015;94(42):e1802.
   PubMed Web of Science ®Google Scholar
• Boveris A. Determination of the production of superoxide radicals and hydrogen peroxide in mitochondria. Methods Enzymol. 1984;105:429–435.
   PubMed Web of Science ®Google Scholar
• Granata S, Zaza G, Simone S, et al. Mitochondrial dysregulation and oxidative stress in patients with chronic kidney disease. BMC Genomics. 2009;10:388.
   PubMed Web of Science ®Google Scholar
• Su H, Jiang L, Carter-Su C, et al. Glucose enhances leptin signaling through modulation of AMPK activity. PLoS One. 2012;7(2):e31636.
   PubMed Web of Science ®Google Scholar
• Yang H, Li M, Chai H, et al. Effects of cyclophilin A on cell proliferation and gene expressions in human vascular smooth muscle cells and endothelial cells. J Surg Res. 2005;123(2):312–319. doi:10.1016/j.jss.2004.08.026
   PubMed Web of Science ®Google Scholar
• Brand MD, Nicholls DG. Assessing mitochondrial dysfunction in cells. Biochem J. 2011;435(2):297–312.
   PubMed Web of Science ®Google Scholar
• Wang P, Heitman J. The cyclophilins. Genome Biol. 2005;6(7):226.
   PubMed Web of Science ®Google Scholar
• Nigro P, Pompilio G, Capogrossi MC. Cyclophilin A: a key player for human disease. Cell Death Dis. 2013;4:e888.
   PubMed Web of Science ®Google Scholar
• Suzuki J, Jin ZG, Meoli DF, et al. Cyclophilin A is secreted by a vesicular pathway in vascular smooth muscle cells. Circ Res. 2006;98(6):811–817.
   PubMed Web of Science ®Google Scholar
• Kim SH, Lessner SM, Sakurai Y, et al. Cyclophilin A as a novel biphasic mediator of endothelial activation and dysfunction. Am J Pathol. 2004;164(5):1567–1574.
   PubMed Web of Science ®Google Scholar
• Sherry B, Yarlett N, Strupp A, et al. Identification of cyclophilin as a proinflammatory secretory product of lipopolysaccharide-activated macrophages. Proc Natl Acad Sci USA. 1992;89(8):3511–3515.
   PubMed Web of Science ®Google Scholar
• Coppinger JA, Cagney G, Toomey S, et al. Characterization of the proteins released from activated platelets leads to localization of novel platelet proteins in human atherosclerotic lesions. Blood. 2004;103(6):2096–2104.
   PubMed Web of Science ®Google Scholar
• Qu X, Wang C, Zhang J, et al. The roles of CD147 and/or cyclophilin A in kidney diseases. Mediators Inflamm. 2014;2014:728673. doi:10.1155/2014/728673.
   PubMedGoogle Scholar
• Jin ZG, Lungu AO, Xie L, et al. Cyclophilin A is a proinflammatory cytokine that activates endothelial cells. Arterioscler Thromb Vasc Biol. 2004;24(7):1186–1191.
   PubMed Web of Science ®Google Scholar
• Sun S, Guo M, Zhang JB, et al. Cyclophilin A (CypA) interacts with NF-κB subunit, p65/RelA, and contributes to NF-κB activation signaling. PLoS One. 2014;9(8):e96211.
   PubMed Web of Science ®Google Scholar
• Arora K, Gwinn WM, Bower MA, et al. Extracellular cyclophilins contribute to the regulation of inflammatory responses. J Immunol. 2005;175(1):517–522.
   PubMed Web of Science ®Google Scholar
• Everson WV, Smart EJ. Influence of caveolin, cholesterol, and lipoproteins on nitric oxide synthase: implications for vascular disease. Trends Cardiovasc Med. 2001;11(6):246–250.
   PubMed Web of Science ®Google Scholar
• Nigro P, Satoh K, O’Dell MR, et al. Cyclophilin A is an inflammatory mediator that promotes atherosclerosis in apolipoprotein E-deficient mice. J Exp Med. 2011;208(1):53–66.
   PubMed Web of Science ®Google Scholar
• Hermann M, Flammer A, Lüscher TF. Nitric oxide in hypertension. J Clin Hypertens (Greenwich). 2006;8(12 Suppl 4):17–29.
   PubMedGoogle Scholar
• Ramachandran S, Venugopal A, Sathisha K, et al. Proteomic profiling of high glucose primed monocytes identifies cyclophilin A as a potential secretory marker of inflammation in type 2 diabetes. Proteomics. 2012;12(18):2808–2821.
   PubMed Web of Science ®Google Scholar
• Ramachandran S, Kartha CC. Cyclophilin-A: a potential screening marker for vascular disease in type-2 diabetes. Can J Physiol Pharmacol. 2012;90(8):1005–1015.
   PubMed Web of Science ®Google Scholar
• Maeda-Hori M, Kosugi T, Kojima H, et al. Plasma CD147 reflects histological features in patients with lupus nephritis. Lupus. 2014;23(4):342–352.
   PubMed Web of Science ®Google Scholar
• Ritov VB, Menshikova EV, Azuma K, et al. Deficiency of electron transport chain in human skeletal muscle mitochondria in type 2 diabetes mellitus and obesity. Am J Physiol Endocrinol Metab. 2010;298(1):E49–E58.
   PubMed Web of Science ®Google Scholar
• Gamboa JL, Billings FT, Bojanowski MT, et al. Mitochondrial dysfunction and oxidative stress in patients with chronic kidney disease. Physiol Rep. 2016;4(9):e12780.
   PubMed Web of Science ®Google Scholar
• Wang W, Wang Y, Long J, et al. Mitochondrial fission triggered by hyperglycemia is mediated by ROCK1 activation in podocytes and endothelial cells. Cell Metab. 2012;15(2):186–200.
   PubMed Web of Science ®Google Scholar
• Tang C, He L, Liu J, et al. Mitophagy: basic mechanism and potential role in kidney diseases. Kidney Dis (Basel). 2015;1(1):71–79.
   PubMed Web of Science ®Google Scholar